12/27/2017 10:03:02 pm
Afanasyev B. V. (St. Petersburg, Russia)
Wagemaker G. (Rotterdam, Netherlands)
Zander A.R. (Hamburg, Germany)
Fehse B. (Hamburg, Germany)
Chukhlovin A. B. (St. Petersburg, Russia)
Aleynikova O. V. (Minsk, Belarus)
Borset M. (Trondheim, Norway)
Chechetkin A. V. (St. Petersburg, Russia)
Fibbe W. (Leiden, Netherlands)
Galibin O. V. (St. Petersburg, Russia)
Hölzer D. (Frankfurt a.M., Germany)
Klimko N. N. (St. Petersburg, Russia)
Kolb H.-J. (München, Germany)
Kröger N. (Hamburg, Germany)
Kulagin A. D. (St. Petersburg, Russia)
Lange C. (Hamburg, Germany)
Mamaev N. N. (St. Petersburg, Russia)
Mikhailova N. B. (St. Petersburg, Russia)
Moiseev I. S. (St. Petersburg, Russia)
Nagler A. (Tel-Aviv, Israel)
Nemkov A. S. (St. Petersburg, Russia)
Paramonov I. V. (Kirov, Russia)
Roumiantsev A. G. (Moscow, Russia)
Current issue begins with a review article by Prof. Rüdiger Hehlmann dedicated to modern strategies of chronic myeloid leukemia treatment (CML) and the role of HSCT, which suffi ciently changed upon introduction of tyrosine kinase inhibitors. His considerations are mostly based on the results of the big CML Study IV, concerning imatinib dosage, or combined therapy with imatinib and cytarabine or interferon α in newly diagnosed patients in chronic phase. The issues of stopping imatinib therapy are discussed.
In his article, Prof. Axel R.Zander considers indications for HSCT in a clinically heterogenous group of chronic myeloproliferative diseases. Distinct molecular defects discovered over last decades are now subjected to specifi c targeted therapy which provides long-term remission states in most patients with chronic myeloid leukemia, primary myelofibrosis, however, using allogeneic HSCT in advanced and high-risk cases.
Some controversies occurring during selection of acute myeloblastic leukemia patients for alo-HSCT are critically evaluated by Prof. Robert P. Gale. To his opinion, the previously used and newer statistic approaches are not accurate enough to predictably discriminate high-risk patients, even if based on the known risk factors of the patients and individual tumor biology.
Dr. Marina O. Popova et al., describe their clinical experience with HIV-infected lymphoma patients treated by autologous HSCT, survival and relapse rate at 12 months aft er transplantation. The matched case-control study was performed at a single institution, (CIC725 EBMT center) designed to prospectively evaluate the safety and efficiency of ASCT for the patients with HIV-related lymphoma.
Another original article is presented by Dr. Ivan S. Moiseev and co-authors, being dedicated to intensively studied cyclophosphamide (Cy) treatment for the graft -versus-host disease. Its comparison with calcineurin inhibitor-based prophylaxis shows distinct benefi t of Cy therapy with respect to the main clinical HSCT outcomes and results.
A clinical case of common variable immunodefi ciency (CVID) and the main approaches to its diagnostics are described in a report by Dr. Andrey V. Kozlov et al. A number of immunological and genetic tests were performed, including new-generation sequencing provided several recognized clinical criteria for the CVID diagnostics.
The items discussed in the article by Prof. Alexander S. Nemkov and Yi Zhang concern probable role of endothelial dysfunction in cardiac disease and potential long-term favorable effects of intracoronary administration of the bone marrow mononuclear cells.
T is CTT issue also contains a synopsis of Regional clinical protocol for Hodgkin’s disease treatment using PET-assisted control and novel targeted drugs (Boris V. Afanasyev et al.). This protocol is endorsed by the leading clinical specialists from St. Petersburg.
For Russian readers, the full text of the multicenter observational program for the North-Western Russia is published in Russian language as well.
Professor Axel R. Zander (Germany), Co-Editor-in Chief, CTT Journal
Professor Gerard Wagemaker (Netherlands), Co-Editor-in Chief, CTT Journal
Nadejda V. Medvedeva5, Georgii M. Manikhas6, Sergey V. Voloshin7, Vladimir M. Moiseenko8, Tatyana V. Shneider9